ATYPICAL RESPONDERS LANDSCAPE REVIEW ∙ OCTOBER, 2017 43 13. Mohseni, M. and B.H. Park, PIK3CA and KRAS mutations predict for response to everolimus therapy: now that’s RAD001. J Clin Invest, 2010. 120(8): p. 2655-8. 14. Abrams, J., et al., National Cancer Institute’s Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book, 2014: p. 71-6. 15. Al-Ahmadie, H., et al., Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer Discov, 2014. 4(9): p. 1014-21. 16. Wagle, N., et al., Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov, 2014. 4(5): p. 546-53. 17. Iyer, G., et al., Genome sequencing identifies a basis for everolimus sensitivity. Science, 2012. 338(6104): p. 221. 18. Imielinski, M., et al., Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest, 2014. 124(4): p. 1582-6. 19. Zardavas, D. and M. Piccart-Gebhart, Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer. Am Soc Clin Oncol Educ Book, 2015. 35: p. e183-90. 20. Kuderer, N.M., et al., Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. JAMA Oncol, 2016. 21. Gambacorti-Passerini, C., et al., Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst, 2011. 103(7): p. 553-61. 22. Mills, G.B., Functional proteomics characterization of breast cancer, in San Antonio Breast Cancer Symposium. 2015: San Antonio, TX. 23. Finn, R.S., A. Aleshin, and D.J. Slamon, Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res, 2016. 18(1): p. 17. 24. Caino, M.C., et al., PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc Natl Acad Sci U S A, 2015. 112(28): p. 8638-43. 25. Grisham, R.N., et al., Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol, 2015. 33(34): p. 4099-105. 26. Prasad, V. and A. Vandross, Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clin Proc, 2015. 90(12): p. 1639-49. 27. Ingelman-Sundberg, M., Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J, 2005. 5(1): p. 6-13.